Search

Your search keyword '"Thompson Jr, Ian M."' showing total 74 results
Start Over Author "Thompson Jr, Ian M."
74 results on '"Thompson Jr, Ian M."'

1. Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy

Author

Eng, Stefan E., Basasie, Benjamin, Lam, Alfonso, John Semmes, O., Troyer, Dean A., Clarke, Geoffrey D., Sunnapwar, Abhijit G., Leach, Robin J., Johnson-Pais, Teresa L., Sokoll, Lori J., Chan, Daniel W., Tosoian, Jeffrey J., Siddiqui, Javed, Chinnaiyan, Arul M., Thompson, Jr., Ian M., Boutros, Paul C., and Liss, Michael A.

Published
2024
Full Text
View/download PDF

2. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

Author

Wang, Anqi, Shen, Jiayi, Rodriguez, Alex A., Saunders, Edward J., Chen, Fei, Janivara, Rohini, Darst, Burcu F., Sheng, Xin, Xu, Yili, Chou, Alisha J., Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Plym, Anna, Sahimi, Ali, Hoffman, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Laisk, Triin, Figuerêdo, Jéssica, Muir, Kenneth, Ito, Shuji, Liu, Xiaoxi, Uchio, Yuji, Kubo, Michiaki, Kamatani, Yoichiro, Lophatananon, Artitaya, Wan, Peggy, Andrews, Caroline, Lori, Adriana, Choudhury, Parichoy P., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokolorczyk, Dominika, Lubinski, Jan, Rentsch, Christopher T., Cho, Kelly, Mcmahon, Benjamin H., Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Borge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Andreas, Stroomberg, Hein V., Batra, Jyotsna, Chambers, Suzanne, Horvath, Lisa, Clements, Judith A., Tilly, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordstrom, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie, Cook, Michael B., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Koutros, Stella, Beane Freeman, Laura E., Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Geraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Butler, Ebonee N., Mohler, James L., Taylor, Jack A., Kogevinas, Manolis, Dierssen-Sotos, Trinidad, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Pilie, Patrick, Yu, Yao, Bohlender, Ryan J., Gu, Jian, Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Brenner, Hermann, Chen, Xuechen, Holleczek, Bernd, Schöttker, Ben, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine M., Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Abraham, Aswin, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer, Petrovics, Gyorgy, Casey, Graham, Wang, Ying, Tettey, Yao, Lachance, Joseph, Tang, Wei, Biritwum, Richard B., Adjei, Andrew A., Tay, Evelyn, Truelove, Ann, Niwa, Shelley, Yamoah, Kosj, Govindasami, Koveela, Chokkalingam, Anand P., Keaton, Jacob M., Hellwege, Jacklyn N., Clark, Peter E., Jalloh, Mohamed, Gueye, Serigne M., Niang, Lamine, Ogunbiyi, Olufemi, Shittu, Olayiwola, Amodu, Olukemi, Adebiyi, Akindele O., Aisuodionoe-Shadrach, Oseremen I., Ajibola, Hafees O., Jamda, Mustapha A., Oluwole, Olabode P., Nwegbu, Maxwell, Adusei, Ben, Mante, Sunny, Darkwa-Abrahams, Afua, Diop, Halimatou, Gundell, Susan M., Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Kachuri, Linda, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Preuss, Michael H., Loos, Ruth J. F., Zawistowski, Matthew, Zöllner, Sebastian, Lu, Zeyun, Van Den Eeden, Stephen K., Easton, Douglas F., Ambs, Stefan, Edwards, Todd L., Mägi, Reedik, Rebbeck, Timothy R., Fritsche, Lars, Chanock, Stephen J., Berndt, Sonja I., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Gaziano, J. Michael, Justice, Amy C., Mancuso, Nick, Terao, Chikashi, Eeles, Rosalind A., Kote-Jarai, Zsofia, Madduri, Ravi K., Conti, David V., and Haiman, Christopher A.

Published
2023
Full Text
View/download PDF

5. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.

Author

Iyer, Gopa, Tangen, Catherine M., Sarfaty, Michal, Regazzi, Ashley M., Lee, I-Ling, Fong, Megan, Choi, Woonyoung, Dinney, Colin P.N., Flaig, Thomas W., Thompson Jr, Ian M., Lerner, Seth P., McConkey, David J., and Rosenberg, Jonathan E.

Subjects
DNA repair, CANCER invasiveness, NEOADJUVANT chemotherapy, BLADDER cancer, NUCLEOTIDE sequencing
Abstract

PURPOSE: Alterations in DNA damage response (DDR) genes, including ERCC2 , have been correlated with response to neoadjuvant cisplatin-based chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). The SWOG 1314 (S1314) trial enrolled patients with MIBC who received one of two NAC regimens followed by radical cystectomy. We examined the prevalence of DDR alterations in NAC responders versus nonresponders and correlated DDR alteration status with response. METHODS: Pretreatment tumor specimens from 179 evaluable patients underwent next-generation sequencing (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets assay). Associations were determined between any or only deleterious alterations within nine predefined DDR genes, or any alterations in ERCC2 , and progression-free survival (PFS) and overall survival using Cox regression, and, in a subset of evaluable patients, pathologic response (complete response, pT0, or downstaging to

Published
2024
Full Text
View/download PDF

6. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.

Author

Barata, Pedro, Tangen, Catherine, Plets, Melissa, Thompson Jr, Ian M., Narayan, Vivek, George, Daniel J., Heng, Daniel Y.C., Shuch, Brian, Stein, Mark, Gulati, Shuchi, Tretiakova, Maria, Tripathi, Abhishek, Bjarnason, Georg A., Humphrey, Peter, Adeniran, Adebowale, Vaishampayan, Ulka, Alva, Ajjai, Zhang, Tian, Cole, Scott, and Lara Jr, Primo N.

Published
2024
Full Text
View/download PDF

7. Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24

Author

Karunamuni, Roshan A., Huynh-Le, Minh-Phuong, Fan, Chun C., Thompson, Wesley, Lui, Asona, Martinez, Maria Elena, Rose, Brent S., Mahal, Brandon, Eeles, Rosalind A., Kote-Jarai, Zsofia, Muir, Kenneth, Lophatananon, Artitaya, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Blot, William J., Zheng, Wei, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Park, Jong Y., Lin, Hui-Yi, Taylor, Jack A., Bensen, Jeannette T., Mohler, James L., Fontham, Elizabeth T. H., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Romana, Marc, Leach, Robin J., John, Esther M., Fowke, Jay H., Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Cullen, Jennifer, Petrovics, Gyorgy, Parent, Marie-Élise, Hu, Jennifer J., Sanderson, Maureen, Mills, Ian G., Andreassen, Ole A., Dale, Anders M., and Seibert, Tyler M.

Published
2022
Full Text
View/download PDF

8. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Author

Conti, David V., Darst, Burcu F., Moss, Lilit C., Saunders, Edward J., Sheng, Xin, Chou, Alisha, Schumacher, Fredrick R., Olama, Ali Amin Al, Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Sahimi, Ali, Hoffmann, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Muir, Kenneth, Lophatananon, Artitaya, Wan, Peggy, Le Marchand, Loic, Wilkens, Lynne R., Stevens, Victoria L., Gapstur, Susan M., Carter, Brian D., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokołorczyk, Dominika, Lubiński, Jan, Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Børge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Martin Andreas, Iversen, Peter, Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Horvath, Lisa, Clements, Judith A., Tilley, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordström, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie J., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Geybels, Milan S., Koutros, Stella, Freeman, Laura E. Beane, Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Burnet, Neil, Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Fontham, Elizabeth T. H., Mohler, James, Taylor, Jack A., Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Weaver, Brandi, Brenner, Hermann, Cuk, Katarina, Holleczek, Bernd, Saum, Kai-Uwe, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Mancuso, Nicholas, Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, and Haiman, Christopher A.

Published
2021
Full Text
View/download PDF

10. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Author

Schumacher, Fredrick R., Al Olama, Ali Amin, Berndt, Sonja I., Benlloch, Sara, Ahmed, Mahbubl, Saunders, Edward J., Dadaev, Tokhir, Leongamornlert, Daniel, Anokian, Ezequiel, Cieza-Borrella, Clara, Goh, Chee, Brook, Mark N., Sheng, Xin, Fachal, Laura, Dennis, Joe, Tyrer, Jonathan, Muir, Kenneth, Lophatananon, Artitaya, Stevens, Victoria L., Gapstur, Susan M., Carter, Brian D., Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr, Ian M., Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Clements, Judith, Horvath, Lisa, Tilley, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Nordström, Tobias, Pharoah, Paul, Pashayan, Nora, Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Albanes, Demetrius, Weinstein, Stephanie, Wolk, Alicja, Håkansson, Niclas, West, Catharine M. L., Dunning, Alison M., Burnet, Neil, Mucci, Lorelei A., Giovannucci, Edward, Andriole, Gerald L., Cussenot, Olivier, Cancel-Tassin, Géraldine, Koutros, Stella, Beane Freeman, Laura E., Sorensen, Karina Dalsgaard, Orntoft, Torben Falck, Borre, Michael, Maehle, Lovise, Grindedal, Eli Marie, Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Travis, Ruth C., Key, Tim J., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Ingles, Sue Ann, Stern, Mariana C., Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Guo, Xin, Wang, Guomin, Sun, Zan, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., FitzGerald, Liesel M., Kibel, Adam S., Drake, Bettina F., Vega, Ana, Gómez-Caamaño, Antonio, Szulkin, Robert, Eklund, Martin, Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Penney, Kathryn L., Stampfer, Meir, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Stanford, Janet L., Cybulski, Cezary, Wokolorczyk, Dominika, Lubinski, Jan, Ostrander, Elaine A., Geybels, Milan S., Nordestgaard, Børge G., Nielsen, Sune F., Weischer, Maren, Bisbjerg, Rasmus, Røder, Martin Andreas, Iversen, Peter, Brenner, Hermann, Cuk, Katarina, Holleczek, Bernd, Maier, Christiane, Luedeke, Manuel, Schnoeller, Thomas, Kim, Jeri, Logothetis, Christopher J., John, Esther M., Teixeira, Manuel R., Paulo, Paula, Cardoso, Marta, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Lin, Daniel W., Newcomb, Lisa F., Lessel, Davor, Gamulin, Marija, Kulis, Tomislav, Kaneva, Radka, Usmani, Nawaid, Singhal, Sandeep, Slavov, Chavdar, Mitev, Vanio, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, Xu, Jianfeng, Khaw, Kay-Tee, Cannon-Albright, Lisa, Pandha, Hardev, Michael, Agnieszka, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., Lindstrom, Sara, Turman, Constance, Ma, Jing, Hunter, David J., Riboli, Elio, Siddiq, Afshan, Canzian, Federico, Kolonel, Laurence N., Le Marchand, Loic, Hoover, Robert N., Machiela, Mitchell J., Cui, Zuxi, Kraft, Peter, Amos, Christopher I., Conti, David V., Easton, Douglas F., Wiklund, Fredrik, Chanock, Stephen J., Henderson, Brian E., Kote-Jarai, Zsofia, Haiman, Christopher A., Eeles, Rosalind A., The Profile Study, Australian Prostate Cancer BioResource (APCB), The IMPACT Study, Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium (BPC3), The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Cancer of the Prostate in Sweden (CAPS), Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS), and The Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium

Published
2018
Full Text
View/download PDF

11. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Author

Conti, David V., Darst, Burcu F., Moss, Lilit C., Saunders, Edward J., Sheng, Xin, Chou, Alisha, Schumacher, Fredrick R., Olama, Ali Amin Al, Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Sahimi, Ali, Hoffmann, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Muir, Kenneth, Lophatananon, Artitaya, Wan, Peggy, Le Marchand, Loic, Wilkens, Lynne R., Stevens, Victoria L., Gapstur, Susan M., Carter, Brian D., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokołorczyk, Dominika, Lubiński, Jan, Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Børge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Martin Andreas, Iversen, Peter, Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Horvath, Lisa, Clements, Judith A., Tilley, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordström, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie J., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Geybels, Milan S., Koutros, Stella, Freeman, Laura E. Beane, Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Burnet, Neil, Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Fontham, Elizabeth T. H., Mohler, James, Taylor, Jack A., Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Weaver, Brandi, Brenner, Hermann, Cuk, Katarina, Holleczek, Bernd, Saum, Kai-Uwe, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Mancuso, Nicholas, Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, and Haiman, Christopher A.

Published
2021
Full Text
View/download PDF

12. Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic.

Author

Sun, Grace, Dizon, Don S., Szczepanek, Connie M., Petrylak, Daniel P., Sparks, Dana B., Tangen, Catherine, Lara Jr, Primo "Lucky" N., Thompson Jr, Ian M., and Blanke, Charles David

Subjects
PSYCHOLOGICAL burnout, CLINICAL trials, JOB stress, LEADERSHIP, LABOR demand, LABOR turnover, COVID-19 pandemic, MEDICAL research, ONCOLOGY
Abstract

The article focuses on the impact of the COVID-19 pandemic on the clinical trials enterprise, particularly in oncology research. The topics include the challenges of personnel shortage, negative impacts on clinical trial processes, and the need for changes in staff retention, training, and hiring practices to improve the clinical trials ecosystem.

Published
2023
Full Text
View/download PDF

13. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).

Author

Agarwal, Neeraj, Tangen, Catherine M., Hussain, Maha H.A., Gupta, Shilpa, Plets, Melissa, Lara, Primo N., Harzstark, Andrea L., Twardowski, Przemyslaw W., Paller, Channing J., Zylla, Dylan, Zibelman, Matthew R., Levine, Ellis, Roth, Bruce J., Goldkorn, Amir, Vaena, Daniel A., Kohli, Manish, Crispino, Tony, Vogelzang, Nicholas J., Thompson Jr, Ian M., and Quinn, David I.

Published
2022
Full Text
View/download PDF

14. Absolute Prostate Specific Antigen after 6 Months of Androgen Deprivation Therapy Is a Predictor of Overall and Cancer-Specific Mortality in Men with Hormone-Sensitive Prostate Cancer.

Author

Dursun, Furkan, Chen-Pin Wang, MacCarthy, Daniel, Mansour, Ahmed M., Pruthi, Deepak K., Kaushik, Dharam, Thompson Jr., Ian M., and Liss, Michael A.

Subjects
PROSTATE-specific antigen, ANDROGEN deprivation therapy, PROSTATE cancer patients, LOG-rank test, OVERALL survival
Abstract

Purpose: We sought to determine if absolute prostate specific antigen (PSA) value after 6 months of androgen deprivation therapy (ADT) is predictive of subsequent survival in patients with prostate adenocarcinoma. Materials and Methods: We performed a retrospective review of men receiving care within the Veterans Health Administration who initiated ADT for prostate adenocarcinoma. We used low- (-0.2 ng/ml), intermediate- (>0.2 to 4 ng/ml) and high-risk (>4 ng/ml) absolute PSA values after 6e9 months of ADT, previously described in Southwest Oncology Group trial 9346. The primary endpoints were all-cause mortality and prostate cancer-specific mortality (PCSM). Kaplan-Meier survival curves for each PSA category were estimated and logrank test was conducted. We employed Cox regression analysis adjusted for covariates and inverse propensity score weights associated with PSA categories to estimate the PSA category association with PCSM and all-cause mortality. Results: We identified 9,170 patients in our cohort. Following ADT induction, 3,508 patients had low, 3,419 had intermediate and 2,243 had high PSA values. Two- and 5-year survival rates for low, intermediate and high PSA groups were 93.9% and 85.2% vs 88.6% and 71.2% vs 63.6% and 38.6%, respectively (p <0.0001). Patients in the high and intermediate PSA categories had a 15-fold and 3-fold higher risk of PCSM compared to those with PSA <0.2 ng/ml (p <0.0001). Conclusions: Absolute PSA in hormone-sensitive prostate cancer after 6e9 months of ADT is a predictor of overall mortality and PCSM. This measure can rapidly assess the efficacy of new interventions in phase 2 clinical trials. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

16. Hereditary Cancer Gene Variants in Hispanic Men With a Personal or Family History of Prostate Cancer.

Author

Ramamurthy, Chethan, Stutz, Eric W., Goros, Martin, Gelfond, Jonathan, Johnson-Pais, Teresa L., Thompson Jr, Ian M., Leach, Robin J., and Liss, Michael A.

Subjects
PROSTATE cancer treatment, CANCER genes, GENETIC testing, DNA repair, HEREDITARY cancer syndromes
Abstract

We investigate germline genetic mutations for prostate cancer (PCa) in Hispanic men enrolled in the SABOR cohort. From 1515 men, we identified 263 with a diagnosis of PCa or a first-degree family history. We discovered a 3.8% mutation rate with 70 variants of undetermined significance, which encourages testing of Hispanic men, and building ethnically diverse genetic references. Background: Mutations in several common hereditary cancer genes are associated with prostate cancer, but there is limited information on the prevalence of these mutations in Hispanic men. Materials and Methods: We selected men at high risk for genetic mutations from 1515 Hispanic men enrolled in the San Antonio Biomarkers of Risk for prostate cancer (SABOR) cohort. Inclusion cr iter ia included men with a diagnosis of prostate cancer or a first-degree family history of prostate cancer. We perfor med ger mline genetic testing using the Color Genomics platform, sequencing 30 genes associated with hereditary cancer risk. Additionally, we assessed ancestral informative markers to determine the admixture of the ethnically unique cohort. Results: Of the 275 subjects who met selection cr iter ia, 263 patients had sufficient samples for sequencing. We identified 3.8% of patients (10 of 263) with a pathogenic or likely pathogenic mutation in the 30 genes tested, of whom 70% would not have met established cr iter ia for genetic testing. Six of these mutations were in BRCA1/2 or ATM. There was a significant inverse association between the percentage of Native American ancestry and the risk of prostate cancer, OR 0.11 (95% CI 0.02-0.76, P = .025). Conclusion: Hispanic men with either a personal or family history of prostate cancer carry mutations in hereditary cancer genes at a significant rate, on par with non-Hispanic counterparts with similar risk factors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

17. Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial.

Author

Chadid, Susan, Song, Xiaoling, Schenk, Jeannette M., Gurel, Bora, Lucia, M. Scott, Thompson Jr., Ian M., Neuhouser, Marian L., Goodman, Phyllis J., Parnes, Howard L., Lippman, Scott M., Nelson, William G., De Marzo, Angelo M., and Platz, Elizabeth A.

Subjects
RETINOIDS, BIOPSY, HIGH performance liquid chromatography, BETA carotene, CONFIDENCE intervals, PROSTATITIS, CRYPTOXANTHIN, CAROTENOIDS, LYCOPENE, CAROTENES, VITAMIN A, LOGISTIC regression analysis, ODDS ratio, PROSTATE tumors
Abstract

Non-supplemental carotenoids and retinol may potentiate antioxidant and anti-inflammatory mechanisms. Chronic intraprostatic inflammation is linked to prostate carcinogenesis. We investigated the association of circulating carotenoids and retinol with intraprostatic inflammation in benign tissue. We included 235 men from the Prostate Cancer Prevention Trial placebo arm who had a negative end-of-study biopsy, most (92.8%) done without clinical indication. α-carotene, β-carotene, β-cryptoxanthin, lycopene, and retinol were assessed by high-performance liquid chromatography using pooled year 1 and 4 serum. Presence and extent of intraprostatic inflammation in benign tissue was assessed in 3 (of 6–10) biopsy cores. Logistic (any core with inflammation vs none) and polytomous logistic (some or all cores with inflammation vs none) regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of intraprostatic inflammation by concentration tertile adjusting for age, race, prostate cancer family history, and serum cholesterol. None of the carotenoids or retinol was associated with intraprostatic inflammation, except β-cryptoxanthin, which appeared to be positively associated with any core with inflammation [vs none, T2: OR (95% CI) = 2.67 (1.19, 5.99); T3: 1.80 (0.84, 3.82), P-trend = 0.12]. These findings suggest that common circulating carotenoids and retinol are not useful dietary intervention targets for preventing prostate cancer via modulating intraprostatic inflammation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

Author

Sanda, Martin G., Feng, Ziding, Howard, David H., Tomlins, Scott A., Sokoll, Lori J., Chan, Daniel W., Regan, Meredith M., Groskopf, Jack, Chipman, Jonathan, Patil, Dattatraya H., Salami, Simpa S., Scherr, Douglas S., Kagan, Jacob, Srivastava, Sudhir, Thompson Jr, Ian M., Siddiqui, Javed, Jing Fan, Joon, Aron Y., Bantis, Leonidas E., and Rubin, Mark A.

Published
2017
Full Text
View/download PDF

24. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.

Author

Unger, Joseph M., Till, Cathee, Thompson, Jr., Ian M., Tangen, Catherine M., Goodman, Phyllis J., Wright, Jason D., Barlow, William E., Ramsey, Scott D., Minasian, Lori M., Hershman, Dawn L., and Thompson, Ian M Jr

Subjects
FINASTERIDE, PLACEBOS, PROSTATE cancer prevention, SEXUAL dysfunction, MEDICARE, BENIGN prostatic hyperplasia, DIABETES, ENZYME inhibitors, PROSTATE tumors, CLINICAL trials, MENTAL depression, LONGITUDINAL method, MEDICAL record linkage, PROBABILITY theory, RESEARCH funding, RISK assessment, TIME, URINARY organs, THERAPEUTICS, PREVENTION
Abstract

Background: Finasteride has been found to reduce the risk of low-grade prostate cancer but to have no impact on overall survival. The long-term adverse and beneficial consequences of finasteride have not been examined.Methods: We used a linkage between data from the Prostate Cancer Prevention Trial (PCPT) and Medicare claims. Patients were examined by randomized study arm (finasteride vs placebo for 7 years) for long-term consequences of the intervention, including cardiac, endocrine, and sexual dysfunction, depression, diabetes, and benign prostatic hyperplasia (BPH)-related events. To examine time to events, we used cumulative incidence and Cox regression, adjusting for covariates. All statistical tests were two-sided.Results: A total of 13 935 of 18 880 participants (73.8%) in the PCPT were linked to Medicare claims, with median Medicare follow-up assessment time of 16 years from trial registration. There were no differences between finasteride and placebo participants with respect to important baseline factors or amount of Medicare follow-up assessment time. Finasteride patients had a 10% higher risk of new claims for depression (hazard ratio [HR] = 1.10, 95% confidence interval [CI] = 1.01 to 1.19, P = .04) and a 6% lower risk of procedures for BPH-related events (primarily lower urinary tract symptoms; HR = 0.94, 95% CI = 0.89 to 1.00, P = .03). No other differences were found in rates of long-term consequences of intervention in the two study arms.Conclusions: Finasteride use is associated with reduced need for procedures for relief of BPH-related events and a modest increase in depression. Overall, there is little need to worry about long-term noncancer consequences of finasteride use in those who use it for treatment of symptomatic BPH, hair growth, or prevention of cancer. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

25. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.

Author

Chan, June M., Darke, Amy K., Penney, Kathryn L., Tangen, Catherine M., Goodman, Phyllis J., Gwo-Shu Mary Lee, Tong Sun, Peisch, Sam, Tinianow, Alex M., Rae, James M., Klein, Eric A., Thompson Jr, Ian M., Kantoff, Philip W., and Mucci, Lorelei A.

Abstract

Background: Epidemiologic studies and secondary analyses of randomized trials supported the hypothesis that selenium and vitamin E lower prostate cancer risk. However, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed no benefit of either supplement. Genetic variants involved in selenium or vitamin E metabolism or transport may underlie the complex associations of selenium and vitamin E. Methods: We undertook a case-cohort study of SELECT participants randomized to placebo, selenium, or vitamin E. The subcohort included 1,434 men; our primary outcome was highgrade prostate cancer (N = 278 cases, Gleason 7 or higher cancer). We used weighted Cox regression to examine the association between SNPs and high-grade prostate cancer risk. To assess effect modification, we created interaction terms between randomization arm and genotype and calculated log likelihood statistics. Results: We noted statistically significant (P < 0.05) interactions between selenium assignment, SNPs in CAT, SOD2, PRDX6, SOD3, and TXNRD2, and high-grade prostate cancer risk. Statistically significant SNPs that modified the association of vitamin E assignment and high-grade prostate cancer included SEC14L2, SOD1, and TTPA. In the placebo arm, several SNPs, hypothesized to interact with supplement assignment and risk of high-grade prostate cancer, were also directly associated with outcome. Conclusion: Variants in selenium and vitamin E metabolism/ transport genes may influence risk of overall and high-grade prostate cancer, and may modify an individual man's response to vitamin E or seleniumsupplementation with regards to these risks. Impact: The effect of selenium or vitamin E supplementation on high-grade prostate cancer risk may vary by genotype. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

27. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.

Author

Murtola, Teemu J., Gurel, Bora, Umbehr, Martin, Lucia, M. Scott, Thompson Jr, Ian M., Goodman, Phyllis J., Kristal, Alan R., Parnes, Howard L., Lippman, Scott M., Sutcliffe, Siobhan, Peskoe, Sarah B., Barber, John R., Drake, Charles G., Nelson, William G., De Marzo, Angelo M., and Platz, Elizabeth A.

Abstract

Background: A previous analysis of the placebo arm of the Prostate Cancer Prevention Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified a link between inflammation and higher-grade prostate cancer and serum PSA. Here, we studied these associations in the PCPT finasteride arm. Methods: Prostate cancer cases (N = 197) detected either on a clinically indicated biopsy or on protocol-directed end-ofstudy biopsy, and frequency-matched controls (N = 248) with no cancer on an end-of-study biopsy were sampled from the finasteride arm. Inflammation in benign prostate tissue was visually assessed using digital images of hematoxylin and eosin-stained sections. Logistic regression was used for statistical analysis. Results: In the finasteride arm, 91.6% of prostate cancer cases and 92.4% of controls had at least one biopsy core with inflammation in benign areas (P < 0.001 for difference compared with placebo arm). Overall, the odds of prostate cancer did not differ by prevalence [OR, 0.90;95%confidence interval (CI), 0.44-1.84] or extent (P trend = 0.68) of inflammation. Inflammation was not associated with higher-grade disease (prevalence: OR, 1.07; 95% CI, 0.43-2.69). Furthermore, mean PSA concentration did not differ by the prevalence or extent of inflammation in either cases or controls. Conclusion: The prevalence of intraprostatic inflammation was higher in the finasteride than placebo arm of the PCPT, with no association with higher-grade prostate cancer. Impact: Finasteride may attenuate the association between inflammation and higher-grade prostate cancer. Moreover, the missing link between intraprostatic inflammation and PSA suggests that finasteride may reduce inflammation-associated PSA elevation. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

28. The pendulum swings back: Screening for prostate cancer in 2018.

Author

Thompson, Jr, Ian M. and Thompson, Ian M Jr

Subjects
*PROSTATE cancer, *DIAGNOSIS, *PROSTATE-specific antigen, *COLON cancer, *RANDOMIZED controlled trials, *OVARIAN cancer
Abstract

The article refers to the screening of prostate cancer for early detection and cure of prostate cancer. Topics include views of Hugh Hampton Young on early diagnosis of prostate cancer; diagnosis by serum prostate specific antigen biomarker; and prevalence of prostate cancer in U.S. It also mentions of results found in Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial in U.S and European Randomized Study of Screening for Prostate Cancer in Europe.

Published
2018
Full Text
View/download PDF

29. Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.

Author

Nash, Sarah H., Till, Cathee, Song, Xiaoling, Lucia, M. Scott, Parnes, Howard L., Thompson Jr, Ian M., Lippman, Scott M., Platz, Elizabeth A., and Schenk, Jeannette

Abstract

Background: Findings from epidemiologic studies examining associations of serum retinol and carotenoids with prostate cancer risk have been inconsistent. This case-control study nested in the Prostate Cancer Prevention Trial evaluated associations of serum retinol and carotenoids with total, low-, and high-grade prostate cancer risk in a highly screened study population. Methods: We used logistic regression adjusting for age, family history of prostate cancer, race, body mass index, and serum cholesterol to estimate ORs and 95% confidence intervals (CI) of prostate cancer by quartiles of serum retinol and carotenoids, separately in the placebo (975 cases/1,009 frequency-matched controls) and finasteride (708 cases/743 frequency-matched controls) arms of the trial. Results: Serum retinol concentrations were associated with increased risk of total prostate cancer [OR (95% CI) comparing the highest quartile of serum retinol with the lowest: 1.30 (1.00-1.68)] and high-grade prostate cancer [OR (95% CI), 1.74 (1.14-2.68)] in the placebo arm of the trial only. Also in the placebo arm, there was a moderate positive association of a-carotene with risk of total prostate cancer [OR (95%CI), 1.32 (1.01-1.73)]. None of the other carotenoids was associated with prostate cancer risk in the placebo arm. No associations were observed for retinol and carotenoids in the finasteride arm. Conclusion: In the placebo arm of this prospective study, high serum retinol and a-carotene concentrations were associated with increased risk of total and high-grade prostate cancers. Impact: Men with higher levels of serum retinol and a-carotene may be at increased risk for prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

31. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

Author

Yu, Evan Y., Hongli Li, Higano, Celestia S., Agarwal, Neeraj, Pal, Sumanta K., Alva, Ajjai, Heath, Elisabeth I., Lam, Elaine T., Gupta, Shilpa, Lilly, Michael B., Yoshio Inoue, Vogelzang, Nicholas J., Quinn, David I., Cheng, Heather H., Plymate, Stephen R., Hussain, Maha, Tangen, Catherine M., Thompson Jr, Ian M., and Chi, Kim N.

Published
2015
Full Text
View/download PDF

34. Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217).

Author

Gritz, Ellen R., Arnold, Kathryn B., Moinpour, Carol M., Burton-Chase, Allison M., Tangen, Catherine M., Probstfield, Jeffrey F., See, William A., Lieber, Michael M., Caggiano, Vincent, Moody-Thomas, Sarah, Szczepanek, Connie, Ryan, Anne, Carlin, Susie, Hill, Shannon, Goodman, Phyllis J., Padberg, Rose Mary, Minasian, Lori M., Meyskens, Frank L., and Thompson Jr, Ian M.

Abstract

The article discusses study on factors associated with adherence to an end-of-study biopsy in the Prostate Cancer Prevention Trial. It mentions that the systematic modeling process using logistic regression identified factors that are associated with end-of-study (EOS) biopsy adherence. It adds that participants were likely to have the EOS biopsy if they adhere to study visit schedules and procedures.

Published
2014
Full Text
View/download PDF

35. Statin Drug Use is Not Associated with Prostate Cancer Risk in Men Who are Regularly Screened.

Author

Platz, Elizabeth A., Tangen, Catherine M., Goodman, Phyllis J., Till, Cathee, Parnes, Howard L., Figg, William D., Albanes, Demetrius, Neuhouser, Marian L., Klein, Eric A., Lucia, M. Scott, Thompson Jr., Ian M., and Kristal, Alan R.

Subjects
PROSTATE cancer treatment, PROSTATE cancer risk factors, STATINS (Cardiovascular agents), MEDICAL screening, COHORT analysis, PLACEBOS, FOLLOW-up studies (Medicine)
Abstract

Purpose Prospective cohort studies support the hypothesis that statin drug users have a lower risk of aggressive prostate cancer. Whether statin drug use influences the risk of screen detected disease is less clear, possibly because of complex detection biases. Thus, we investigated this association in a setting in which men had low baseline serum prostate specific antigen concentration and were screened annually. Materials and Methods We performed a cohort study of 9,457 men 55 years old or older at randomization to the placebo arm of PCPT (Prostate Cancer Prevention Trial). The men reported new use of medications quarterly. We estimated the multivariable adjusted HR of prostate cancer (574 cases in 62,192 person-years) for statin drug use and duration of use during the trial using Cox proportional hazards regression. Results During 7 years of followup statin drug use during the trial was not associated with the risk of total prostate cancer (HR 1.03, 95% CI 0.82-1.30), or lower grade (HR 0.96, 95% CI 0.71-1.29) or higher grade (HR 1.27, 95% CI 0.85-1.90) prostate cancer. Duration of use during followup was also not associated with the risk of total, or lower or higher grade disease (p trend = 0.7, 0.5 and 0.2, respectively). Conclusions These prospective results do not support the hypothesis that statin drugs protect against prostate cancer in the setting of regular prostate cancer screening. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

36. Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial.

Author

Gurel, Bora, Lucia, M. Scott, Thompson Jr, Ian M., Goodman, Phyllis J., Tangen, Catherine M., Kristal, Alan R., Parnes, Howard L., Hoque, Ashraful, Lippman, Scott M., Sutcliffe, Siobhan, Peskoe, Sarah B., Drake, Charles G., Nelson, William G., De Marzo, Angelo M., and Platz, Elizabeth A.

Abstract

The article discusses the study that determined the association of chronic inflammation in benign prostate tissue with prostate cancer, based on samples from the placebo arm of the Prostate Cancer Prevention Trial. Findings discussed include positive association of chronic inflammation in benign prostate tissue to prostate cancer, especially high grade, and higher odds of prostate cancer for men who has at least one biopsy core with inflammation compared to men with no cores with inflammation.

Published
2014
Full Text
View/download PDF

37. The Diagnostic Value of Adiponectin Multimers in Healthy Men Undergoing Screening for Prostate Cancer.

Author

Medina, Edward A., Xiaoyu Shi, Grayson, Marcia H., Ankerst, Donna P., B. Livi, Carolina, Medina, Maria V., Thompson Jr, Ian M., and Leach, Robin J.

Abstract

The article discusses a study which examined whether adiponectin serves as a biomarker for prostate cancer. Topics discussed include the measurement of high-molecular weight (HMW) and low-molecular weight (LMW) adiponectin, total adiponectin and body mass index (BMI), a decreasing level of adiponectin with an increasing obesity level, and the failure of the results of the study to support adiponectin multimers as biomarkers for prostate cancer.

Published
2014
Full Text
View/download PDF

39. Long-Term Survival of Participants in the Prostate Cancer Prevention Trial.

Author

Thompson Jr., Ian M., Goodman, Phyllis J., Tangen, Catherine M., Pames, Howard L., Minasian, Lori M., Godley, Paul A., Lucia, M. Scott, and Ford, Leslie G.

Subjects
*FINASTERIDE, *PROSTATE cancer prevention, *PROSTATE-specific antigen, *CANCER-related mortality, *TUMOR diagnosis, *THERAPEUTICS
Abstract

The article discusses a study on the use of finasteride to reduce the risk of prostate cancer on Prostate Cancer Prevention Trial (PCPT) participants. Details relating to PCPT are presented. It also discusses statistical analysis, survival analysis and at-risk analysis relating to the PCPT. Particular focus is given to the use of Prostate-Specific Antigen (PSA) testing for reduced mortality from prostate cancer, overdetection of prostate cancer, and diagnosis of low-grade tumors.

Published
2013
Full Text
View/download PDF

40. Vitamin E and the Risk of Prostate Cancer.

Author

Klein, Eric A., Thompson Jr., Ian M., Tangen, Catherine M., Crowley, John J., Lucia, M. Scott, Goodman, Phyllis J., Minasian, Lori M., Ford, Leslie G., Parnes, Howard L., Gaziano, J. Michael, Karp, Daniel D., Lieber, Michael M., Walther, Philip J., Klotz, Laurence, Parsons, J. Kellogg, Chin, Joseph L., Darke, Amy K., Lippman, Scott M., Goodman, Gary E., and Meyskens Jr., Frank L.

Subjects
*VITAMIN E, *SELENIUM, *PROSTATE cancer risk factors, *MALE reproductive organ diseases, *PROSTATE-specific antigen, *CANCER in men, *DIAGNOSIS
Abstract

The article discusses a study which determined the long-term effect of vitamin E and selenium on risk of prostate cancer in relatively healthy men. Statistical analysis showed the significant increase in the risk of prostate cancer among healthy men who received vitamin E dietary supplements. According to data, 620 men in the vitamin E group and 575 men in the selenium group developed prostate cancer, compared with 529 men in the placebo group. Data indicate the frequency of use of prostate-specific antigen (PSA) and digital rectal examination, as well as the rate of prostate cancer detection in all the treatment groups.

Published
2011
Full Text
View/download PDF

41. Degarelix in the Treatment of Prostate Cancer.

Author

Ercole, Barbara and Thompson Jr., Ian M.

Subjects
*ANDROGEN receptors, *LEUPROLIDE, *CASTRATION, *LUTEINIZING hormone releasing hormone, *CLINICAL trials
Abstract

Manipulation of the hypothalamic-pituitary-gonadal axis via androgen deprivation therapy has been in use since the 1940's for the treatment of advanced prostate cancer. Androgen deprivation may be achieved via surgical castration or pharmacological castration. Pharmacological castration is preferred by patients due to its decreased psychological impact on body image and potential reversibility. Gonadotropin releasing hormone (GnRH) agonists have been a mainstay in androgen suppression. Recently degarelix, a GnRH antagonist, has been proven to be as effective and not inferior to GnRH analogues, such as leuprolide, in a phase III trial. Degarelix was found to have no initial testosterone surge, reach castrate levels of testosterone by day three, have no testosterone microsurges, have the ability to keep follicle stimulating hormone suppressed and have lower histaminogenic potency compared to its predecessor abarelix. A review of the pharmacokinetics, clinical trial findings, safety and ongoing debates as to the best application of degarelix is presented. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

42. Q&A.

Author

ESSERMAN, LAURA J. and THOMPSON JR, IAN M.

Published
2016

43. Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial.

Author

Platz, Elizabeth A., Till, Cathee, Goodman, Phyllis J., Parnes, Howard L., Figg, William D., Albanes, Demetrius, Neuhouser, Marian L., Klein, Eric A., Thompson Jr., Ian M., and Kristal, Alan R.

Abstract

The article focuses on the study on men with low blood cholesterol and the link between the use of cholesterol-lowering statin drugs and the advanced stage and possible high-grade prostate cancer. Researchers are investigating the association of low blood cholesterol and the risk of prostate cancer in the Prostate Cancer Prevention Trial. They conclude that a reduced risk of high grade prostate cancer are found in men with low cholesterol.

Published
2009
Full Text
View/download PDF

44. Longitudinal Analysis of Sexual Function Reported by Men in the Prostate Cancer Prevention Trial.

Author

Moinpour, Carol M., Darke, Amy K., Donaldson, Gary W., Thompson, Jr., Ian M., Langley, Connie, Ankerst, Donna Pauler, Patrick, Donald L., Ware, Jr., John E., Ganz, Patricia A., Shumaker, Sally A., Lippman, Scott M., and Coltman, Jr., Charles A.

Subjects
PROSTATE cancer, SEXUAL dysfunction, CANCER prevention, SEXUAL excitement, MEN'S sexual behavior
Abstract

Background The Prostate Cancer Prevention Trial (PCPT) was a randomized, double-blind, placebo-controlled study of the efficacy of finasteride in preventing prostate cancer in 18882 men aged 55 years or older. The PCPT offered an opportunity to prospectively study the effects of finasteride and other covariates on sexual dysfunction. Methods We assessed sexual dysfunction in 17313 PCPT participants during a 7-year period. A battery of questionnaires assessed sexual dysfunction (Sexual Activity Scale score); age; race; SF-36 Mental Health Inventory-5, Physical Function, and Vitality scores; body mass index; smoking status; and the presence of diabetes and hypertension. Assessments began at month 6 after random assignment and included the Sexual Activity Scale score at randomization as a covariate. Two-sided general t tests, with a cutoff of P value less than .05, were used to determine the statistical significance for mixed model effects with correlated random time slopes and intercepts. The changing impact of covariates on sexual dysfunction was also assessed at 6 months, 3.5 years, and 6.5 years after randomization. Results Finasteride increased sexual dysfunction only slightly and its impact diminished over time; the increase in the Sexual Activity Scale score relative to placebo of 3.21 points (95% confidence interval [Cl] = 2.83 to 3.59 points; P<.001) at the first assessment decreased to 2.11 points (95% Cl = 1.44 to 2.81 points; P<.001) at the end of study. These Sexual Activity score values were small on a scale of 0-100, the range observed in the study, and in comparison with individual variation. After adjustment for all covariates, mean sexual dysfunction increased in both arms from baseline (6 months after randomization) by 1.26 Sexual Activity points (95% Cl = 1.16 to 1.36 points; P<.001) per year, corresponding to a cumulative increase of 8.22 points (95% Cl = 7.52 to 8.92 points; P<.001) over the study period. Conclusions The effect of finasteride on sexual functioning is minimal for most men and should not impact the decision to prescribe or take finasteride. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

45. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Author

Lippman, Scott M., Goodman, PhylIis J., Klein, Eric A., Parnes, Howard L., Thompson Jr., Ian M., Kristal, Alan R., SantelIa, Regina M., Probstfield, Jeffrey L., Moinpour, Carol M., Albanes, Demetrius, Taylor, Philip R., Minasian, Lori M., Hoque, Ash Raful, Thomas, Sarah Moody, Crowlev, John J., Gaziano, J. Michael, Stanford, Janet L., Cook, Elise D., Fleshner, Neil E., and Lieber, Michael M.

Subjects
PROSTATE cancer, AFRICAN Americans, SELENIUM, VITAMIN E, CANCER prevention, CANCER patients, MEDICAL care
Abstract

Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 μg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac α-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

46. Early or late hormonal therapy for prostate cancer?

Author

Thompson Jr, Ian M., Crawford, E. David, and deKernion, Jean B.

Abstract

Deals with hormonal therapy for prostate cancer. Role of early hormonal therapy in prostate-specific antigen failures; How to manage the adverse effects of early therapy; Prevention of osteoporosis; Effectiveness of intermittent therapy; Description of the types of hormonal therapy available.

Published
2001

47. Improved Therapy for PSA Recurrence after Prostatectomy.

Author

Thompson, Jr., Ian M. and Thompson, Ian M Jr

Subjects
*PROSTATE-specific antigen, *PROSTATECTOMY, *PROSTATE cancer, *LUTEINIZING hormone releasing hormone, *ANDROGENS
Abstract

The author discusses improved therapy for prostate-specific antigen (PSA) recurrence after prostatectomy in patients having prostate cancer. Topics discussed include indication of disease recurrence as per the levels of PSA; information on replacement of luteinizing hormone-releasing hormone (LHRH) with androgen-deprivation therapy with large dose bicalutamide; and contribution of contribution by the National Clinical Trials Network of the National Cancer Institute, on clinical trials.

Published
2017
Full Text
View/download PDF

48. Focusing PSA Testing on Detection of High-Risk Prostate Cancers by Incorporating Patient Preferences Into Decision Making.

Author

Thompson Jr., Ian M., Leach, Robin J., and Ankerst, Donna P.

Subjects
*PROSTATE-specific antigen, *TUMOR antigens, *MEDICAL screening, *HEALTH risk assessment, *CLINICAL trials, *DIAGNOSIS, *PROSTATE cancer
Abstract

The article discusses the U.S. Preventive Services Task Force's recommendation against prostate-specific antigen (PSA) testing in general population due to the effect of detection and treatment and complications from treatment. Topics discussed include results of randomized clinical trials (RCT) of PSA screening in Europe and the U.S., development of a risk assessment tool to predict outcomes and recommendations for future improvements in decision-making tools.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results